Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 54, Status: Authorised
What is established Stelara (ustekinumab) is a monoclonal antibody drug authorized in the European Union since 2009 for the treatment of several inflammatory diseases including moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It targets two immune system messenger molecules, interleukin 12 (IL-12) and interleukin 23 (IL-23),…
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026
What is established In October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of six new medicines, including treatments for metastatic pancreatic cancer, obesity and type 2 diabetes, achondroplasia in children, and brain tumors in adults and children. The committee also supported extensions of…